The $15 million raise provides near-term runway, but the sharp revenue decline and increasing R&D spend suggest ongoing dilution risk. Investors should closely monitor the Q3 2026 ELPIS II data readout as a critical value inflection point. The PRV monetization agreement may limit upside from regulatory incentives.
LGVN drugs
LGVN drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 18 $0.9760entry
- T+1 · 8mo ago +13.73%α +14.00% · $1.11
- T+5 · 8mo ago −0.31%α +0.41% · $0.9730
- T+20 · 7mo ago +12.70%α +6.66% · $1.10
- T+60 · 5mo ago −21.00%α −32.53% · $0.7710
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Longeveron reported a 50% year-over-year revenue decline for 2025, driven by lower clinical trial and contract manufacturing demand, while net loss widened to $22.7 million. The company raised $15 million in a private placement, extending its cash runway into Q4 2026, and remains on track for pivotal Phase 2b HLHS trial results in Q3 2026. Despite positive clinical and regulatory developments, deteriorating financials dominate the near-term outlook.
Key Financial Metrics
Key Facts
- 2025 revenue was $1.2 million, down 50% from $2.4 million in 2024
- Net loss increased to $22.7 million in 2025 from $16.0 million in 2024
- Cash and cash equivalents dropped to $4.7 million from $19.2 million in 2024
- Raised $15 million in initial closing of a $30 million private placement led by Coastlands Capital and Janus Henderson
- Pivotal Phase 2b ELPIS II trial in HLHS expected to read out in Q3 2026, potentially supporting a BLA submission in 2027
- Investors in the private placement will receive 50% of proceeds from any future Pediatric Priority Review Voucher (PRV) sale related to HLHS
Financial Impact
Revenue down $1.2 million YoY, net loss up $6.7 million, cash burn of $14.5 million in 2025
Risk Factors
- High cash burn and reliance on future financings, increasing dilution risk
- Clinical trial failure risk in HLHS, which is central to the company's BLA and PRV strategy
- Limited revenue diversification and dependence on contract manufacturing and trials
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257647 |
Track record
22 reports on LGVN
3 of 4 bullish or bearish reports moved the stock their way by T+60. Best: +44.65% at T+20 after the Sep 16, 2026 report. 6 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $2.53 Now $2.14 +15.42% settles Feb 12
- Nov 13, 20263d ago SC 13G Neutral 4/10 Entry $2.49 Now $2.14 −14.06% settles Feb 11
- Nov 12, 20264d ago 8-K Bearish 7/10 No price data
- Nov 12, 20264d ago Press Release Bearish 6/10 Entry $2.49 Now $2.14 +14.06% settles Feb 11
- Nov 5, 202611d ago SC 13G/A Bearish 5/10 Entry $1.81 Now $2.14 −18.23% settles Feb 4
- Nov 5, 202611d ago 8-K Neutral 2/10 Entry $1.81 Now $2.14 +18.23% settles Feb 4
- Oct 26, 202621d ago 8-K Neutral 5/10 Entry $1.73 Now $2.14 +23.70% settles Jan 25
- Oct 26, 202621d ago Press Release Mixed 6/10 Entry $1.61 Now $2.14 +33.33% settles Jan 22
- Oct 14, 20264w ago 8-K Neutral 3/10 Entry $1.50 Now $2.14 +42.67% settles Jan 12
- Sep 16, 20268w ago Press Release Bearish 7/10 Entry $2.71 Now $2.14 +21.03% settles Dec 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers